Amylyx Pharmaceuticals, Inc. Common Stock (AMLX)
NASDAQ
38.15
-0.51 (-1.32%)
Closed
Aug 24, 2026
Day's Range
37.4539.38
52 wk Range
8.4741.14
Financial Statements - AMLX - Amylyx Pharmaceuticals, Inc. Common Stock
Revenue
0▼ 100.0%
Net Income
-144.73M▲ 52.0%
EBITDA
-152.76M▲ 21.9%
Free Cash Flow
-123.48M▲ 26.4%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 0 | 87.37M | 380.78M | 22.23M | 0 | 0 |
| Cost of Goods | 0 | 124.63M | 25.44M | 2.99M | 0 | - |
| Gross Profit | 0 | -37.26M | 355.34M | 19.23M | 0 | - |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | -153.29M | -255.67M | 38.80M | -201.34M | -82.68M | -39M |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | -700K | -60.26M | -660K | -551K | -5.27M | -1M |
| Pre Tax Income | -144.68M | -302.13M | 54.29M | -197.60M | -87.93M | -42.28M |
| Income Tax | 46K | -393K | 5.02M | 774K | 0 | - |
| Net Income | -144.73M | -301.74M | 49.27M | -198.37M | -87.93M | -42.28M |
| EPS Basic | -1.53 | -4.43 | 0.73 | -3.39 | -1.592491 | -0.920101 |
| EPS Diluted | -1.53 | -4.43 | 0.7 | -3.39 | -1.592491 | -0.920101 |
| Basic Shares Outstanding | 94.56M | 68.14M | 67.23M | 58.49M | 55.21M | 45.95M |
| Diluted Shares Outstanding | 94.56M | 68.14M | 67.23M | 58.49M | 55.21M | 45.95M |
| Ebit | -153.29M | -255.67M | 38.80M | -201.34M | -82.68M | -39.99M |
| Ebitda | -152.76M | -195.71M | 39.89M | -200.85M | -82.63M | -38.72M |
| Net Income Continuous Operations | -144.73M | -301.74M | 49.27M | -198.37M | -87.93M | -42.28M |
| Minority Interests | - | - | - | - | - | - |
| Preferred Stock Dividends | - | - | - | - | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
